Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Migraine Characteristics and Associated Factors

10 septembre 2026 mis à jour par: Demet Öztürk, Lokman Hekim University

Evaluation of Clinical Characteristics of Migraine and Associated Factors in Individuals Diagnosed With Primary Migraine

This cross-sectional study aims to evaluate the clinical characteristics of migraine and factors associated with migraine-related disability and impact in adults diagnosed with primary migraine. Participants will complete questionnaires assessing sociodemographic and lifestyle characteristics, headache features, neck pain, sleep quality, fatigue, migraine-related disability, and the impact of headache on daily life. Migraine-related disability will be assessed using the Migraine Disability Assessment Scale (MIDAS), and headache impact will be assessed using the Headache Impact Test-6 (HIT-6). In addition, participants will undergo a physical examination including assessment of tender points. The study will investigate the relationships between migraine-related outcomes and clinical and lifestyle factors. No treatment or therapeutic intervention will be administered as part of the study.

Aperçu de l'étude

Statut

Pas encore de recrutement

Les conditions

Intervention / Traitement

Description détaillée

Migraine is a common neurological condition that may substantially affect daily functioning, work or school performance, social participation, and quality of life. The burden of migraine may be influenced not only by headache intensity and frequency but also by associated clinical and lifestyle factors.

This cross-sectional study is designed to characterize migraine-related symptoms and to examine factors associated with migraine-related disability and headache impact in adults with a diagnosis of primary migraine. Data will be collected during a single face-to-face assessment. Participants will complete self-reported measures covering sociodemographic and lifestyle characteristics, headache features, associated symptoms, neck pain, perceived sleep quality, fatigue, migraine-related disability, and the impact of headache on daily life. A physical examination will also be performed to assess predefined tender points.

The study will explore the relationships between migraine-related outcomes and selected clinical and lifestyle characteristics. No therapeutic intervention will be administered, and participation will involve assessment procedures only.

Type d'étude

Observationnel

Inscription (Estimé)

100

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Enfant
  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

The study population will consist of adults aged 18 years or older who have been diagnosed with primary migraine by a neurologist. Individuals who meet the study eligibility criteria and voluntarily agree to participate will be recruited through study announcements shared via social media platforms, including LinkedIn, WhatsApp, and Instagram. Eligible participants will be invited to Lokman Hekim University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, where all study assessments will be conducted face to face. The study population will include individuals with different clinical characteristics of migraine in order to evaluate migraine-related disability, headache impact, associated symptoms, lifestyle-related factors, and physical examination findings.

La description

Inclusion Criteria:

  • Aged 18 years or older
  • Diagnosed with primary migraine by a neurologist
  • Having a history of migraine for at least 3 months
  • Able to understand and complete the study questionnaires and assessments
  • Willing to participate voluntarily in the study

Exclusion Criteria:

  • Presence of a secondary headache disorder
  • Presence of another neurological or systemic condition that may substantially affect headache characteristics or interfere with the study assessments
  • Presence of a cognitive or communication impairment that prevents reliable completion of the questionnaires
  • Incomplete completion of the study assessments or questionnaires

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

Cohortes et interventions

Groupe / Cohorte
Intervention / Traitement
Individuals With Primary Migraine
Adults diagnosed with primary migraine who meet the study eligibility criteria and undergo the study assessments, including questionnaires evaluating migraine characteristics, migraine-related disability, headache impact, neck pain, sleep quality, fatigue, and lifestyle-related factors, as well as tender point examination. No therapeutic intervention will be administered.
Autre: Observational assessment
Participants completed assessment form. No intervention was administered.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Migraine-Related Disability
Délai: Baseline
Migraine-related disability will be assessed using the Migraine Disability Assessment Scale (MIDAS). The MIDAS consists of five items evaluating the number of days over the previous 3 months in which headache caused missed or substantially reduced productivity in work/school, household activities, and family/social/leisure activities. The total score is calculated by summing the number of days reported across the five items, with higher scores indicating greater migraine-related disability.
Baseline

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Headache Impact
Délai: Baseline
Headache impact will be assessed using the Headache Impact Test-6 (HIT-6). The HIT-6 consists of six items evaluating the impact of headache on daily activities, fatigue, emotional well-being, and concentration. The total score ranges from 36 to 78, with higher scores indicating a greater impact of headache on daily life.
Baseline
Headache Pain Intensity
Délai: Baseline
Headache pain intensity will be assessed using a 10-cm Visual Analog Scale (VAS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates unbearable pain. Higher scores indicate greater headache intensity.
Baseline
Neck Pain Intensity
Délai: Baseline
Neck pain intensity will be assessed using a 10-cm Visual Analog Scale (VAS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates unbearable pain. Higher scores indicate greater neck pain intensity.
Baseline
Perceived Sleep Quality
Délai: Baseline
Perceived sleep quality will be assessed using a 10-cm Visual Analog Scale. Participants will rate their sleep quality from 0 to 10, with higher scores indicating better perceived sleep quality.
Baseline
Daily Step Count
Délai: Baseline
Daily physical activity will be represented by the participant's average daily step count obtained from personal devices such as smartphones or wearable activity trackers.
Baseline
Presence of Associated Migraine Symptoms
Délai: Baseline
The presence of migraine-associated symptoms, including nausea, vomiting, photophobia, phonophobia, osmophobia, dizziness, and imbalance, will be recorded based on participant self-report.
Baseline

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Lokman Hekim University

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 octobre 2026

Achèvement primaire (Estimé)

1 novembre 2026

Achèvement de l'étude (Estimé)

1 décembre 2026

Dates d'inscription aux études

Première soumission

10 septembre 2026

Première soumission répondant aux critères de contrôle qualité

10 septembre 2026

Première publication (Réel)

16 septembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

16 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

10 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Mots clés

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • 2026-BA

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner